title: Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
abstract: OBJECTIVE
  The treatment for superficial G3 transitional cell carcinoma (TCC) of the urinary bladder remains controversial. It is important to reveal the clinical features of superficial G3 bladder cancer that can be treated conservatively.
  
  
  METHODS
  A total of 39 patients with primary superficial bladder cancer (Ta, T1) with G3 components but without concomitant carcinoma in situ (CIS), who had been treated initially with transurethral resection (TUR), were retrospectively analyzed for factors related to tumor recurrence, progression and survival. The patients were 34 males and five females whose age ranged from 49 to 85 years (average, 68 years). Initial tumor stages were Ta in one patient and T1 in 38. Initial treatments were TUR alone in 18 patients and TUR with adjuvant therapy (intravesical chemotherapy or BCG therapy) in 21. Factors examined included age, gender, morphology, size and number of tumors and adjuvant therapies.
  
  
  RESULTS
  Follow-up periods were 3-138 months (median, 37 months). Tumor recurrence, progression and cancer death were observed in 23, seven and four cases, respectively. The 5-year progression-free rate (75%) and survival rate (83%) in 39 patients with G3 did not show a statistically significant difference from those of the 109 patients with G1 or the 187 patients with G2 superficial bladder cancer who were treated with TUR initially. Only the rate of recurrence of patients with G3 was significantly higher than that of patients with G2 or G1. Adjuvant therapies reduced the recurrence rate of the patients with G3. Only tumor morphology, papillary or non-papillary, affected both the progression-free rate and the survival rate of patients with G3. There were no statistically significant differences associated with other factors.
  
  
  CONCLUSIONS
  The results suggest that superficial G3 bladder cancer could be treated with TUR initially, especially for papillary tumors.
authors.affiliation: Department of Urology, Okayama University Medical School, Okayama, Japan. saika@iwa.att.ne.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Saika
authors.forename: Tomoyasu
authors.initials: T
authors.lastname: Tsushima
authors.forename: Yasutomo
authors.initials: Y
authors.lastname: Nasu
authors.forename: Ryoji
authors.initials: R
authors.lastname: Arata
authors.forename: Haruki
authors.initials: H
authors.lastname: Kaku
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Kusaka
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kumon
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000401:mortality / Q000601:surgery*; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000601:surgery*; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000601:surgery*